breast cancer

News

ASCO 25: Roche places Itovebi marker in breast cancer

Roche's Itovebi has become the first PI3K inhibitor to extend survival in HR-positive, HER2-negative breast cancer with a PIK3CA mutation.

News

New data could move Enhertu into early breast cancer

AstraZeneca and Daiichi Sankyo's Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage breast cancer for the first time.

News

Woman with breast cancer covering her chest with her hands

Enhertu poised to move first line in HER2+ breast cancer

New data could make HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the first time.

News

Vials on a conveyor belt - pharma manufacturing

Trodelvy-Keytruda pairing hits the spot in breast cancer

Gilead Sciences has cemented the role of its TROP2 drug Trodelvy in triple-negative breast cancer with a study win in combination with MSD's Keytruda.

News

Pill that can slow breast cancer cleared for NHS use

AstraZeneca's oral drug Truqap will soon be available for people with advanced breast cancer via the NHS in England, as long as testing is available.

News

AZ, Daiichi get EU okay for breast cancer drug Datroway

AstraZeneca and Daiichi Sankyo have claimed approval from the European Commission for Datroway, their TROP2-directed ADC for breast cancer.

ASCO 25: Roche places Itovebi marker in breast cancer

New data could move Enhertu into early breast cancer

Enhertu poised to move first line in HER2+ breast cancer

Trodelvy-Keytruda pairing hits the spot in breast cancer

Pill that can slow breast cancer cleared for NHS use

AZ, Daiichi get EU okay for breast cancer drug Datroway

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

breast cancer

Editor's Picks